Stocks · Health care · Pharmaceutical Preparations

NEKTAR THERAPEUTICS

NKTR Clue Score14
United States Fiscal year ends December CIK 0000906709 Results filed 13 Aug 2026

What the insiders did Net selling

By person

8 insiders · 16 transactions
3.5×

Howard W. Robin holds only 3.5 times base salary in stock. $3.93M of shares against $1.11M in salary for 2025.

Salary from the company's own proxy. The shares are what Howard W. Robin last reported holding, valued at $71.98, the price Common Stock was last bought or sold at on the open market here, on 18 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Howard W Robin
President & CEO
—
$1.42M (8) scheduled
−$1.42M
54,627
$3.93M
—
Jonathan Zalevsky
Chief R&D Officer
—
$974.18K (7) scheduled
−$974.18K
9,570
$688.85K
—
Mark Andrew Wilson
Chief Legal Officer
—
$34.20K (1)
−$34.20K
21,585
$1.55M
—
R Scott Greer
Director
—
—
—
22,239
$1.60M
+9.9%
Roy A Whitfield
Director
—
—
—
21,185
$1.52M
+10.4%
Robert Chess
Director
—
—
—
19,299
$1.39M
+11.6%
Jeffrey Robert Ajer
Director
—
—
—
4,277
$307.86K
+87.8%
Diana Brainard
Director
—
—
—
3,904
$281.01K
+105.0%

No percentages here. This company's share count has moved by a factor of 9.8 over the window, from 19,018,573 to 186,103,588 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.